Fortunato Ciardiello

Research interests

Publications

• Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00275-9

• Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.02088

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

  European Journal of Heart Failure · 2020 · 10.1002/ejhf.1920

• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1908075

• Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30027-0

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235

• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)32517-x

• Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer

  JAMA Oncology · 2016 · https://doi.org/10.1001/jamaoncol.2016.3797

• Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00150-9

• Mechanisms of resistance to EGFR-targeted drugs: lung cancer

  ESMO Open · 2016 · https://doi.org/10.1136/esmoopen-2016-000060

• Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.59.4812

• Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.57.9334

• Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

  Modern Pathology · 2015 · https://doi.org/10.1038/modpathol.2015.98

• Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies

  European Journal of Cancer · 2012 · https://doi.org/10.1016/j.ejca.2012.11.018

• Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

  European Journal of Cancer · 2012 · https://doi.org/10.1016/j.ejca.2012.02.057

• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds236

• Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.33.5091

• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70130-3

• KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70209-6

• Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

  Nature Reviews Clinical Oncology · 2009 · https://doi.org/10.1038/nrclinonc.2009.111

• EGFR Antagonists in Cancer Treatment

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmra0707704

• Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.13.2183

• Chronic inflammation and oxidative stress in human carcinogenesis

  International Journal of Cancer · 2007 · https://doi.org/10.1002/ijc.23192

• ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

  PubMed · 2002

• Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

  PubMed · 2002

• Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

  PubMed · 2001

• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

  PubMed · 2001

• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  PubMed · 2000

• Epidermal growth factor-related peptides and their receptors in human malignancies

  Critical Reviews in Oncology/Hematology · 1995 · https://doi.org/10.1016/1040-8428(94)00144-i

Current projects

No projects listed.